Insider Selling: Alimera Sciences, Inc. (ALIM) SVP Sells 25,500 Shares of Stock

Alimera Sciences, Inc. (NASDAQ:ALIM) SVP Philip Ashman sold 25,500 shares of the firm’s stock in a transaction dated Friday, January 19th. The shares were sold at an average price of $1.20, for a total transaction of $30,600.00. Following the completion of the transaction, the senior vice president now directly owns 12,750 shares in the company, valued at $15,300. The sale was disclosed in a document filed with the SEC, which is available at this link.

Philip Ashman also recently made the following trade(s):

  • On Wednesday, January 17th, Philip Ashman sold 25,500 shares of Alimera Sciences stock. The shares were sold at an average price of $1.23, for a total transaction of $31,365.00.

Alimera Sciences, Inc. (NASDAQ ALIM) traded down $0.04 during mid-day trading on Friday, reaching $1.20. 329,291 shares of the company’s stock were exchanged, compared to its average volume of 180,769. The firm has a market cap of $82.98, a P/E ratio of -3.87 and a beta of 2.15. The company has a debt-to-equity ratio of -0.71, a quick ratio of 4.65 and a current ratio of 4.84. Alimera Sciences, Inc. has a 12 month low of $1.11 and a 12 month high of $1.72.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. analysts anticipate that Alimera Sciences, Inc. will post -0.27 earnings per share for the current year.

A number of research analysts recently weighed in on ALIM shares. Zacks Investment Research raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Monday, January 8th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Alimera Sciences in a report on Wednesday, November 22nd. Cowen reiterated a “buy” rating on shares of Alimera Sciences in a report on Thursday, November 2nd. Finally, ValuEngine downgraded shares of Alimera Sciences from a “sell” rating to a “strong sell” rating in a report on Sunday, December 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $3.38.

An institutional investor recently raised its position in Alimera Sciences stock. PNC Financial Services Group Inc. raised its holdings in Alimera Sciences, Inc. (NASDAQ:ALIM) by 24.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 180,300 shares of the biopharmaceutical company’s stock after acquiring an additional 35,200 shares during the period. PNC Financial Services Group Inc. owned approximately 0.28% of Alimera Sciences worth $251,000 at the end of the most recent quarter. 41.78% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/19/insider-selling-alimera-sciences-inc-alim-svp-sells-25500-shares-of-stock.html.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply